Xenon Pharmaceuticals News

Xenon Pharmaceuticals Analyst Ratings

BenzingaApr 12 07:02 ET

Xenon Pharmaceuticals Analyst Ratings

BenzingaApr 10 09:46 ET

Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress

TipRanksMar 5 01:35 ET

Xenon Pharmaceuticals Analyst Ratings

BenzingaMar 1 08:10 ET

RBC Trims Price Target on Xenon Pharmaceuticals to $55 From $56, Keeps Outperform, Speculative Risk

MT NewswiresMar 1 08:09 ET

Buy Rating Justified by Xenon Pharmaceuticals' Advanced Epilepsy Program and Growth Prospects in Neuroscience

TipRanksMar 1 02:45 ET

Maintaining Buy Rating on Xenon Pharmaceuticals With a $60 Target Amidst XEN1101 Clinical Advancements

TipRanksJan 8 18:45 ET

Citigroup Initiates Coverage On Xenon Pharmaceuticals With Buy Rating, Announces Price Target of $62

BenzingaJan 4 04:47 ET

Xenon Pharmaceuticals Analyst Ratings

BenzingaJan 4 04:46 ET

B of A Securities Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $56

BenzingaJan 2 10:48 ET

Xenon Pharmaceuticals Analyst Ratings

BenzingaJan 2 10:46 ET

Xenon Pharmaceuticals Analyst Ratings

BenzingaDec 18, 2023 10:56 ET

Baird Initiates Coverage On Xenon Pharmaceuticals With Outperform Rating, Announces Price Target of $63

BenzingaDec 8, 2023 05:29 ET

Xenon Pharmaceuticals Analyst Ratings

BenzingaDec 8, 2023 05:27 ET

RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $56

BenzingaNov 28, 2023 04:31 ET

Xenon Pharmaceuticals Analyst Ratings

BenzingaNov 28, 2023 04:29 ET

Maintained Buy Rating on Xenon Pharmaceuticals: Promising Signals for XEN1101 Despite Trial Challenges

TipRanksNov 27, 2023 18:15 ET

Xenon Pharmaceuticals Analyst Ratings

BenzingaNov 9, 2023 10:44 ET

Xenon Pharmaceuticals Analyst Ratings

BenzingaOct 24, 2023 13:35 ET

RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $51 Price Target

BenzingaSep 22, 2023 10:54 ET